journal article·2019-12-04Open access

Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis

Ning Hu, Xuan Gong, Shijie Yin, Qi Li, Hao Chen, Yuwan Li, Feilong Li, Leilei Qing, Jianye Yang, Sizheng Zhu, Jiawei Wang, Junchao Li

Abstract

Osteoarthritis (OA) is a major public health concern for which a reliable non-invasive treatment option has yet to be developed. In the present study, we investigated the effects of saxagliptin, a novel dipeptidyl peptidase IV (DPP-4) inhibitor, on several important aspects of the pathophysiology of OA using primary human chondrocytes. The results of real-time PCR and ELISA analyses show that saxagliptin treatment significantly decreased mRNA and protein expression of three key cartilage degrading enzymes: matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13. The results of western blot confirmed that this decrease in MMP-1, -3, and -13 expression prevented degradation of type II collagen. We also found that saxagliptin significantly inhibited expression of a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS)-4 and ADAMTS-5, which was reflected by markedly decreased degradation of aggrecan. Inhibition of DPP-4 by saxagliptin also reduced oxidative stress in human primary chondrocytes as evidenced by decreased production of reactive oxygen species (ROS) and increased glutathione (GSH) levels. Additionally, the results of western blot analysis show that the effects of saxagliptin are mediated through the p38/IκBα/NF-κB pathway, which is considered an important treatment target for OA. These findings suggest a potential role for saxagliptin as a novel treatment against OA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammatory mediators and NSAID effects · Osteoarthritis Treatment and Mechanisms · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University

Outpatient Department, Chongqing General Hospital

Department of Orthopaedics, The University of Hong Kong-Shenzhen Hospital

Department of Orthopaedics, Chongqing Beibei Traditional Chinese Medical Hospital

Department of Orthopaedics, Chongqing Yubei People’s Hospital

Department of Orthopaedics, Chongqing Dazu People’s Hospital

College of Material Science and Engineering, Chongqing University

Funding

the National Natural Science Foundation of China

References (34)

Show source-provided references
1. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39:237–246.
2. 10.3892/mmr.2016.552310.3892/mmr.2016.5523 ↗
3. 10.1002/art.2152310.1002/art.21523 ↗
4. 10.4103/1995-7645.22357710.4103/1995-7645.223577 ↗
5. 10.1097/01.ASN.0000077413.41276.1710.1097/01.ASN.0000077413.41276.17 ↗
6. 10.1016/j.joca.2016.01.35410.1016/j.joca.2016.01.354 ↗
7. 10.1172/JCI6409810.1172/JCI64098 ↗
8. 10.1093/rheumatology/ker13410.1093/rheumatology/ker134 ↗
9. 10.1038/nrrheum.2010.19610.1038/nrrheum.2010.196 ↗
10. 10.1136/ard.61.suppl_2.ii7810.1136/ard.61.suppl_2.ii78 ↗
11. 10.1186/ar40110.1186/ar401 ↗
12. 10.1172/JCI1056410.1172/JCI10564 ↗
13. 10.1038/nm.199810.1038/nm.1998 ↗
14. 10.1002/jcb.2329810.1002/jcb.23298 ↗
15. 10.2174/13894500978712290510.2174/138945009787122905 ↗
16. 10.1007/s11914-011-0070-310.1007/s11914-011-0070-3 ↗
17. 10.4049/jimmunol.090039010.4049/jimmunol.0900390 ↗
18. Traynor K. FDA approves saxagliptin for type 2 diabetes. Am J Health Syst Pharm. 2009;66:1513.10.2146/news090069 ↗
19. 10.1007/s40264-016-0399-810.1007/s40264-016-0399-8 ↗
20. 10.1210/jc.2015-117610.1210/jc.2015-1176 ↗
21. 10.1111/j.1476-5381.2011.01537.x10.1111/j.1476-5381.2011.01537.x ↗
22. 10.1038/s41419-017-0217-y10.1038/s41419-017-0217-y ↗
23. 10.1186/s12891-015-0615-110.1186/s12891-015-0615-1 ↗
24. Mahmoud RK, El-Ansary AK, El-Eishi HH. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem 2005;54:248–257.
25. 10.22203/eCM.v021a1610.22203/eCM.v021a16 ↗
26. 10.3390/biom501019410.3390/biom5010194 ↗
27. 10.1002/art.2233410.1002/art.22334 ↗
28. 10.1016/j.redox.2013.12.01610.1016/j.redox.2013.12.016 ↗
29. 10.1038/ncpendmet078610.1038/ncpendmet0786 ↗
30. 10.1016/j.bbamcr.2007.03.01010.1016/j.bbamcr.2007.03.010 ↗
31. 10.1136/rmdopen-2015-00006110.1136/rmdopen-2015-000061 ↗
32. 10.1016/j.biopha.2018.04.01810.1016/j.biopha.2018.04.018 ↗
33. 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-410.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4 ↗
34. 10.1016/S0092-8674(00)80406-710.1016/S0092-8674(00)80406-7 ↗